Chile Patent System

Chile's pharmaceutical patent system is more liberal than Argentina's or Brazil's in terms of granting pharmaceutical patents, but has specific provisions driven by US-Chile FTA obligations: (1) Pharmaceutical patentability in Chile: unlike Argentina, which bars patents on polymorphs, new salts, new formulations, and new uses without enhanced therapeutic efficacy, Chile generally allows pharmaceutical patents on new chemical entities, as well as on new polymorphs, new salts, new formulations, and second medical uses — subject to INAPI examination for novelty and inventive step. This is closer to the US/EPO approach than the Argentina approach; (2) US-Chile FTA pharmaceutical provisions: the US-Chile FTA (Free Trade Agreement, in force since 2004) contains Chapter 17 IP provisions including: pharmaceutical patent linkage — requiring Chile to implement a patent-drug linkage system linking generic drug marketing authorizations (from Chile's ISP — Instituto de Salud Pública) to patent status notification; data exclusivity for new chemical entities (5 years); biologics data protection (5 years in Chile — shorter than US 12 years BPCIA); Chile's patent linkage system: the Pauta de Vinculación (linkage provision) requires the ISP to notify patent holders when a generic drug marketing authorization application is filed for a product covered by a pharmaceutical patent registered in Chile's Patent Register (maintained by INAPI). Patent holders can file for preliminary injunctions at Chilean civil courts; (3) Compulsory licensing in Chile: Chile's Ley 19.039 Article 51 allows compulsory licensing on grounds of: non-working (3 years from grant or 4 years from filing, whichever is later); public health emergencies — Article 51 Bis added public health emergency compulsory licensing in 2021 (post-COVID reform under Law 21.355). Chile issued a government use authorization for Sofosbuvir (Hepatitis C, Gilead) in 2015 — an early use of a government use authorization in Chile's regulatory history; (4) Pharmaceutical industry in Chile: Chile's domestic pharmaceutical industry is relatively small; major companies include: Laboratorio Chile (Sanitas/Grünenthal subsidiary — generic and OTC drugs; largest Chilean domestic pharma company); CFR Pharmaceuticals (consolidated into Abbott/Mylan); RECALCINE (generic drugs); AB-BIOTICS (Lactobacillus probiotics/microbiome patents, acquired by Kaneka Japan); (5) Biotech: BioSinapse (biotech startup ecosystem in Valparaíso/Santiago); Chile's Fundación para la Innovación Agraria (FIA) funds agricultural biotech R&D; INIA (Instituto de Investigaciones Agropecuarias) files plant variety protection and agricultural biotech patents.

Chile's geography creates unique innovation contexts: (1) Atacama Desert solar energy: the Atacama Desert (Antofagasta, Chile) receives the world's highest solar irradiation (approximately 9,500 Wh/m²/day at Salar de Atacama at altitude) — creating a competitive advantage for both solar power and green hydrogen production. IP in this sector: Cerro Dominador CSP project (Atacama — Chile's first commercial concentrated solar power plant with molten salt thermal energy storage; 110MW CSP + 100MW PV; first commercial CSP in Latin America; molten salt receiver and storage system patents; Aurora Solar Energy development); Colbún, Enel Chile, Engie Chile solar and wind power project patents; Highly Efficient PV panel installation methods for high-altitude, high-UV-intensity, high-wind-speed Atacama conditions; (2) Green hydrogen — 'Green Hydrogen Roadmap for Chile' (Ministry of Energy, 2020): Chile aims to be a top-3 global green hydrogen exporter by 2030. IP interest: Atacama solar power → green hydrogen electrolysis → ammonia synthesis (green ammonia for agricultural fertilizers) → green methanol (shipping fuel); HIF Global (HIGHLY Innovative Fuels — based in Houston and Santiago; Porsche-backed eFuel plant in Punta Arenas, Patagonia — synthetic methanol/eFuels from wind power electrolysis + CO2; first commercial scale eFuel [e-methanol] plant in the world; manufacturing process patents; Porsche eFuel IP collaboration); Acciona, ENAP (Empresa Nacional del Petróleo), ENGIE Chile green hydrogen projects; (3) Astronomy and space technology: the Atacama Desert's extreme altitude (4,500m+) and low humidity make it the world's best site for ground-based astronomy. Chile hosts: ALMA (Atacama Large Millimeter/submillimeter Array — joint ESO/NRAO/NAOJ; radio astronomy, no patents but antenna array technology co-developed with European/US/Japanese contractors who hold relevant IP); ESO ELT (Extremely Large Telescope — under construction at Cerro Armazones; ESO consortium-developed mirror+AO system [adaptive optics] patents with European contractors [SCHOTT for 798 hexagonal M1 mirror segments, TNO Netherlands for segment polishing, ADS International for positioners]); Gemini Observatory (international consortium); La Silla, Paranal, Las Campanas observatories. Chile has developed an astrotech innovation sector: CATA (Centro de Astrofísica y Tecnologías Afines); Millennium Astrophysics Institute; (4) Aquaculture and fisheries: Chile is the world's second-largest Atlantic salmon aquaculture producer (after Norway). Chilean salmon farming patents: innovative sea lice management systems (lasers, warm water, hydrogen peroxide bath patents licensed from Norwegian companies); RAS (Recirculating Aquaculture Systems) patents for closed-containment salmon production; novel salmon feed ingredients (SalmonoidTech, BioMar Chile, EWOS Chile); AquaBounty salmon genetics and vaccination IP; (5) Chilean wine industry: Chile is the world's 7th largest wine exporter. IP: vineyard genomics (INIA plant breeders' rights for Carménère, País, Cabernet Sauvignon clones); wine production process innovations (fermentation management, oxidation control); Universidad de Chile/Pontificia Universidad Católica de Chile wine science research.

Yes — Chile has a 1-year grace period for an applicant's own prior disclosures under Article 42 of Ley 19.039 de Propiedad Industrial. This grace period protects applicants who have publicly disclosed their invention before filing a patent application: (1) Who is covered: the grace period covers disclosures made by the patent applicant OR disclosures made by persons who obtained the information from the applicant (e.g., through a license agreement, collaboration, or breach of confidence). It does NOT cover independent disclosures by third parties — if a competitor independently discovers and publishes the same invention before your filing date, that disclosure is still prior art against your application; (2) Duration: the grace period is 12 months (1 year) before the Chilean filing date, or before the priority date if priority is claimed under the Paris Convention; (3) What triggers the grace period: any public disclosure by the applicant or those deriving information from the applicant — conference presentations, scientific publications, journal articles, public demonstrations, trade shows, product launches, investor pitches, social media posts, or any other public disclosure; (4) Comparison with US AIA § 102(b)(1): the Chile and US grace periods have similar structures — both protect own disclosures within 12 months of filing. However, the US AIA § 102(b)(1) is considered somewhat broader in practice; (5) No grace period for third-party disclosures: if an inventor publishes a paper, and then a different third party independently publishes on the same topic two weeks later, that third-party publication is still prior art against the Chilean patent application if filed after the third-party publication date; (6) Contrast with EPC countries: countries using the European Patent Convention (EPC) have NO general grace period — only a narrow 6-month exception for disclosures at officially recognized international exhibitions. A researcher in Germany, France, or Spain who publishes before filing permanently destroys European patent rights. Chile's 1-year grace period is therefore more similar to US patent law than to European patent law; (7) Practical advice: even though Chile has a 1-year grace period, best practice remains to file the patent application BEFORE any public disclosure. The grace period is a safety net for situations where disclosure has already occurred, not a recommended filing strategy.

Chile's lithium significance stems from the combination of extraordinarily high-concentration lithium brines in the Salar de Atacama (Atacama Salt Flat) with the global transition to lithium-ion batteries for electric vehicles and energy storage. The importance and the IP: (1) The Atacama's unique geology: the Salar de Atacama is a hypersaline lake system approximately 3,000m above sea level in the Atacama Desert. Its brines contain lithium at concentrations of approximately 1,500–2,000 mg/L — among the highest in the world. High brine concentration means lower processing cost per tonne of lithium produced; (2) Scale of reserves: Chile holds approximately 9.2 million tonnes of lithium reserves (USGS 2024 estimate) — approximately 37% of global proven reserves. Combined with Argentina and Bolivia (the other 'Lithium Triangle' countries), South America contains approximately 58% of global lithium reserves; (3) Solar evaporation process: the basic lithium production process in the Atacama is solar evaporation — pumping lithium-rich brine into shallow evaporation ponds where solar energy (extremely intense in the Atacama) concentrates the lithium from ~0.15% to approximately 6% over 12–18 months. After evaporation, the concentrated brine is processed to remove magnesium, calcium, boron, and other impurities, then converted to lithium carbonate (Li2CO3) or lithium hydroxide monohydrate (LiOH·H2O) for battery markets. SQM and Albemarle have developed proprietary optimizations of this process — brine management algorithms, pond geometry optimization, impurity removal chemistry — protected by patents; (4) Battery-grade specification patents: battery manufacturers (CATL, Panasonic, LG Energy Solution, Samsung SDI, BYD) require precise lithium specifications. Converting salar brine to battery-grade lithium hydroxide monohydrate involves purification steps that SQM and Albemarle have patented; (5) Direct Lithium Extraction (DLE) threat and opportunity: DLE technologies bypass the slow solar evaporation step, extracting lithium directly from brine using ion-exchange sorbents, electrochemical cells, or membrane separation. DLE is faster (hours vs. 12–18 months), uses less water, and can process lower-grade brines. Multiple companies hold DLE patents: EnergySource International (geothermal brine lithium extraction), Standard Lithium, Anson Lithium, Allkem/Livent (now Arcadium Lithium), Lake Resources (Australia), E3 Lithium, and others. SQM and Albemarle are investing in DLE R&D at the Atacama to defend their competitive position; (6) State control and IP: Chile's new Lithium Strategy (announced 2023 by President Boric) proposes that the Chilean state (CODELCO and/or ENAMI) take equity stakes in future lithium operations, potentially affecting IP ownership arrangements.

Chile and Argentina are the two most important patent markets in South America alongside Brazil, but they have taken different approaches to pharmaceutical patent policy: (1) Chile: more liberal pharmaceutical patent system. Chile generally allows pharmaceutical patents on new chemical entities (NCEs), and also on new polymorphs, new salts, new formulations, new routes of administration, and new medical uses/second indications — subject to INAPI's substantive examination for novelty and inventive step. INAPI examiners assess whether the claimed invention is actually new and non-obvious, but Chile does not apply a special 'enhanced therapeutic efficacy' filter that Argentina uses. This means that a pharmaceutical company seeking to patent a new crystalline form of an existing drug or a new formulation can be granted a Chilean patent if INAPI's examination finds the claims novel and non-obvious — similar to the EPO or USPTO approach; (2) Argentina: most restrictive pharmaceutical patent system in Latin America. Argentina's 2012 Joint Examination Guidelines (INPI + Ministry of Health + Ministry of Industry) apply heightened scrutiny to pharmaceutical patent applications, refusing patents on: new polymorphs (different crystalline forms of known compounds) unless they demonstrate enhanced therapeutic efficacy; new salts/esters/derivatives of known compounds without enhanced therapeutic efficacy; new formulations/compositions without enhanced therapeutic efficacy; new dosage forms or routes of administration without enhanced therapeutic efficacy; second medical uses (new indications for known drugs) — generally rejected; fixed-dose combinations without synergistic therapeutic efficacy; (3) Practical implications: a pharmaceutical company whose drug is losing patent protection can file 'evergreening' secondary patents in Chile and likely have them granted by INAPI — the same secondary patent applications would face much higher barriers to grant in Argentina; (4) US-Chile FTA pharmaceutical provisions: the US-Chile FTA (2004) requires Chile to: implement patent-drug linkage (generic MA applications notify patent holders); provide 5 years of pharmaceutical data exclusivity for new chemical entities; provide 5 years of biologics data exclusivity (shorter than US 12-year BPCIA); allow for compulsory licensing only in limited circumstances consistent with TRIPS; (5) The balance: Chile's system is more innovation-friendly for pharmaceutical patent protection than Argentina's, which places greater emphasis on generic drug access. Brazil sits between the two — allowing pharmaceutical patents with additional administrative hurdles (ANVISA technical prior consent for pharma patents).

Chile is the world's dominant copper producer, accounting for approximately 27% of global copper mine production in 2023 — roughly 5.6 million tonnes out of approximately 22 million tonnes globally. This dominant position, combined with declining ore grades in Chile's aging copper deposits, drives significant investment in mining technology: (1) CODELCO (Corporación Nacional del Cobre de Chile — state-owned, world's largest copper producer ~1.7 million tonnes/yr): CODELCO's major mines include Chuquicamata (Antofagasta — world's largest open-pit copper mine transitioning to underground block caving), El Teniente (O'Higgins — world's largest underground copper mine), Andina, Salvador, Gabriela Mistral, and Radomiro Tomic. CODELCO patents: block caving technology for ultra-deep block caves (El Teniente and Chuquicamata Underground at 1,000m+ depth); continuous mining equipment for panel caving; mine-to-mill optimization systems; geomechanics instrumentation for monitoring slope stability in open-pit highwalls; (2) BHP Escondida (Atacama Desert — world's largest single copper mine by production, ~1.2 million tonnes/yr; BHP 57.5%, Rio Tinto 30%, JECO 10%): concentrator optimization patents; copper flotation reagent efficiency patents for processing low-grade sulfide ore at Escondida's declining grades; seawater desalination for mining — Escondida uses a desalination plant on the Pacific coast to supply freshwater for the Atacama operation (water scarcity is critical; desalination system patents); renewable energy integration for Escondida's massive power demand; (3) Declining ore grade challenge: Chilean copper average ore grade has fallen from approximately 1.5% Cu in 2000 to approximately 0.6–0.7% Cu currently. Processing lower grade ore requires: more ore to be moved per tonne of copper produced; higher energy consumption per tonne of copper; improved flotation efficiency (more sophisticated froth flotation chemistry, reagents, cell design); innovations in SX-EW (Solvent Extraction-Electrowinning) for oxide ores; These challenges drive significant R&D investment and patent activity; (4) Where IP is filed: major mining companies (BHP, Rio Tinto, Anglo American, Antofagasta, Freeport-McMoRan) operating in Chile file their mining technology patents at EPO, USPTO, and via PCT — not primarily at INAPI. Chilean national mining patents are filed by CODELCO, Chilean mining equipment manufacturers (Metso, Sandvik, Epiroc Chile offices generate local innovations), and University of Chile / Pontificia Universidad Católica de Chile mining engineering departments. Technology suppliers (Metso Outotec, FLSmidth, Weir Group) hold copper processing equipment patents that are exploited in Chile under license.

Chile has developed one of the world's most ambitious national green hydrogen strategies, driven by the extraordinary renewable energy resources of the Atacama Desert (world's highest solar irradiation) and Patagonia (world-class wind resources). This creates a unique emerging IP landscape: (1) National Green Hydrogen Strategy (2020, Ministry of Energy): Chile's strategy targets production of green hydrogen at the lowest global cost by 2030, with ambitions to become a top-3 green hydrogen exporter by 2040. Target: green hydrogen production cost below $1.5/kg by 2030, below $1.0/kg by 2040 (current costs are approximately $3–5/kg, with fossil hydrogen at approximately $1–2/kg); (2) Atacama Desert advantage: the Atacama Desert receives solar irradiation of approximately 9,500 Wh/m²/day at Salar de Atacama altitude (sea level equivalent would be approximately 5,500 Wh/m²/day — the Atacama is significantly more intense than the US Southwest desert). This enables: PV solar electricity at extremely low cost (Chile has achieved some of the world's lowest PV electricity prices in its power auctions — below $20/MWh at peak); direct electrolysis from PV electricity with high capacity factors; integration with seawater desalination for hydrogen production water; CSP (Concentrated Solar Power) with molten salt thermal storage enables 24-hour green hydrogen production; (3) HIF Global (Highly Innovative Fuels — Houston and Santiago): Porsche-backed company that built the world's first commercial-scale e-methanol/eFuel plant (Haru Oni) in Punta Arenas, Patagonia (southernmost Chile). The plant uses Patagonian wind power + CO2 captured from air (DAC — Direct Air Capture) + water electrolysis (green hydrogen) to produce synthetic eFuel (e-methanol → e-gasoline/e-aviation fuel) for Porsche's motorsport fleet and eventual commercial ICE vehicles. HIF holds process patents in: electrolytic hydrogen production integration with wind power; CO2 capture from air (DAC) at the Patagonia scale; methanol synthesis from green H2 + CO2 (reverse methanol process); fuel quality control for synthetic eFuels; this is the first-ever commercial-scale eFuel plant — the patents are genuinely novel; (4) Antofagasta and Atacama green hydrogen projects: multiple green hydrogen projects in the Antofagasta (Atacama) region are in development: ENAP (Empresa Nacional del Petróleo) H2 Magallanes; Engie Chile; Acciona Energía; AES Andes; (5) IP significance: as green hydrogen becomes a commodity, the IP differentiation will be in: water electrolysis efficiency improvements (proton exchange membrane [PEM] electrolysis, alkaline electrolysis, solid oxide electrolysis — GreenHydrogen, Nel Hydrogen, ITM Power, Thyssenkrupp Nucera IP); ammonia synthesis from green hydrogen (green ammonia — Yara International leading); hydrogen liquefaction for transport; hydrogen compression and storage for export.